Biogen Inc v Medeva Plc

A patent claim is insufficient where its breadth exceeds the technical contribution to the art actually disclosed (so-called 'Biogen insufficiency'), and the same requirement of an enabling disclosure governs both sufficiency and entitlement to a priority date.